CardioMech Expands Mitral Leadership Team

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

March 18, 2019

CardioMech AS, today announced it has expanded its leadership team with the election of two new board directors: Kathleen Tune of Fourth Element Capital, and Frederik Groenewegen of 415 CAPITAL, a board advisor, Vic Bertrand, and appointed Daniele Salamone as Vice President of Finance.

The CardioMech device is a highly differentiated technology designed to significantly improve the standard of care for patients suffering from severe, symptomatic degenerative mitral regurgitation due to prolapse or flail. “I am extremely pleased to announce this expansion of CardioMech’s mitral leadership team with the addition of four experienced medical technology professionals,” said Rick Nehm, President and CEO of CardioMech.

Kathleen is a proven healthcare executive with over 25 years of investing and business experience. She co-founded and manages a healthcare investment firm Fourth Element Capitaland previously was a partner at the healthcare investment firm Thomas, McNerney & Partners.“CardioMech is participating in one of the most innovative segments of medicine with a significant unmet need,” said KathleenTune.Frederik, co-founder and managing director of 415 CAPITAL, a designated medical technology investment firm whose senior team has backed over 45 novel medical device technologies, including CoreValve (Medtronic), CardiAQ (Edwards Lifesciences), and Claret (Boston Scientific).

Frederik brings extensive fundraising, M&A, and commercialization experience to the company’s team. “Transcatheter mitral valve repair is a hot market segment, and we believe the company is strongly positioned for a leadership role in chordal repair,” said FrederikGroenewegen.

Vic, a veteran medical technology investor, and director who was appointed as a company advisor is also an entrepreneur with30 years’ experience in medical technology, manufacturing, and real estate, said, “I am thrilled to support Rick and the CardioMech team on their mission to bring this innovative and much-needed solution to the affected population globally,” said Vic Bertrand.

Daniele Salamone, CardioMech’snew Vice President of Finance, brings tremendous experience to the company to accelerate and guide the creation of shareholder value. He is an experienced strategy consultant with expertise in corporate development, strategic planning, and M&A transactions. His background is in innovation with startups and corporate innovation initiatives. He has direct experience with structural heart device commercialization. He was most recently atThe Boston Consulting Group



Related Articles